Consolidation Seen Changing Nature Of Indian Generics Industry
This article was originally published in PharmAsia News
Executive Summary
The face that India's pharmaceutical makers have presented to the rest of the industry may be changing. The Indian industry, comprised primarily of makers of generic drugs, has been undergoing a consolidation of late, a move likely to increase market power for the participants, but also reduce competition, thus increasing prices for consumers. The move by Ranbaxy Laboratories to sell to Japan's Daiichi Sankyo has led to speculation about the future of India's generics-making industry. (Click here for more